Status:
COMPLETED
Molecular Detection of Antibiotic Resistance and H Pylori Eradication
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Helicobacter Pylori Infection
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
H pylori eradication failure with recommended triple therapy is mainly related to antibiotic resistance. However,IN VITRO culture of H pylori is uneasy and is not performed in routine practice. A mole...
Detailed Description
At the present time, H pylori infection is treated with a standard triple therapy. Treatment of naïve patients with triple therapy ( PPI+amoxicillin+clarithromycin for 7 days) markedly decreased last ...
Eligibility Criteria
Inclusion
- H pylori infection bacteriologically confirmed
- Age \> 18 years
- Naïve patient or one failure of the first line recommended treatment
- Patient referred to one out of the centres participating in the study
Exclusion
- H pylori positive patient with at least failure of two lies of treatment
- patients with previous adverse event with PPI, amoxicillin, clarithromycin, levofloxacin or metronidazole
- PPI or antibiotic treatment in progressor stopped for less than 4 weeks
- patient with other severe sickness
Key Trial Info
Start Date :
February 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2013
Estimated Enrollment :
1386 Patients enrolled
Trial Details
Trial ID
NCT01168063
Start Date
February 1 2010
End Date
March 1 2013
Last Update
November 8 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Henri Mondor Hospital
Créteil, France, 94010